en · de · es · fr · pt
sr9009-notes.peptides6088.com › News › Background And Mechanism — Beginner to Advanced

Background And Mechanism — Beginner to Advanced

By Editorial Desk · published 2025-08-03 · last reviewed 2025-09-06 · News

Everything below concerns Stenabolic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Related pages on this site

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Reference notes

Nicholson at Birkbeck College, University of London and later at Imperial College London. In 1984, Nicholson showed 1H NMR spectroscopy could potentially be used to diagnose diabetes mellitus, and later pioneered the application of pattern recognition methods to NMR spectroscopic data. In 1994 and 1996, liquid chromatography mass spectrometry metabolomics experiments were performed by Gary Siuzdak while working with Richard Lerner (then president of the Scripps Research Institute) and Benjamin Cravatt, to analyze the cerebral spinal fluid from sleep deprived animals. One molecule of particular interest, oleamide, was observed and later shown to have sleep inducing properties. This work is one of the earliest such experiments combining liquid chromatography and mass spectrometry in metabolomics. In 2005, the first metabolomics tandem mass spectrometry database, METLIN, for characterizing human metabolites was developed in the Siuzdak laboratory at the Scripps Research Institute. METLIN has since grown and as of 2025, METLIN contains MS/MS experimental data on over 960,000 molecular standards and other chemical entities, each compound having experimental tandem mass spectrometry data generated from molecular standards at multiple collision energies and in positive and negative ionization modes. METLIN is the largest repository of tandem mass spectrometry data of its kind. The dedicated academic journal Metabolomics first appeared in 2005, founded by its current editor-in-chief Roy Goodacre.

== Medical uses == Nadolol is used to treat hypertension and for long-term treatment of angina pectoris and is approved by the FDA for these purposes. It is regularly used off-label for control of heart rate in people with atrial fibrillation, prevention of migraine headaches; prevention of bleeding veins in people with portal hypertension caused by cirrhosis; and to treat people with high levels of thyroid hormone. Nadolol is the preferred beta-blocker in the management of patients with LQTS for prevention of ventricular arrhythmia. It is more efficacious than selective beta blockers or propranolol in the prevention of breakthrough cardiac events. Similarly, it is the preferred type of beta blocker for treatment of patients with CPVT, as it has been shown to be more efficacious than selective beta blockers, like atenolol or bisoprolol. Nadolol has the advantage of once daily dosing and thus improved patient compliance. For patients with decreased kidney function, nadolol may be dosed less often. It has also been found to be useful (off-label) for several neurological disorders such as the prevention of migraine attacks, attention deficit/hyperactivity disorder(ADHD) and its use has been explored as a treatment for essential tremor and Parkinson's disease but neither is well established. Nadolol has been used to treat anxiety as well.

13 June – Science and the 2022 Russian invasion of Ukraine:Groups of academics report how global science community could help Ukraine via an action plan, including for helping organizing (re)vitalization of Ukrainian science and reconstruction in the future. On the same day, a researcher outlined a number of possible major policy-based actions that could mitigate the energy and resource crises caused or exacerbated by the war. Russian space agency Roscosmos announces the intent to, unilaterally and hazardously, take over paused telescope eROSITA, launched in collaboration with Germany (4 June). A science journalist outlines some of the food system-related environmental impacts of the war (21 June). A study reports a number of humanitarian, economic, and financial impacts of the war (23 June). 15 June Astronomers identify J1144 as the fastest-growing black hole of the last nine billion years, consuming matter equivalent to one Earth every second, as well as being the most luminous quasi-stellar object of that period. Researchers report Lac-Phe as the most significantly induced circulating metabolite in two animal models of exercise which – including via chronic administration – reduces food intake and suppresses obesity. 20 June A study suggests global food miles CO2 emissions are 3.5–7.5 times higher than previously estimated, with transport accounting for about 19% of total food-system emissions, albeit shifting towards plant-based diets remains substantially more important.

Sources: en.wikipedia.org

Reference notes

== Commercial use == D-Ribose-L-cysteine is used as an ingredient in several commercially marketed dietary supplements, particularly products promoted for general antioxidant support and cellular health. The primary commercial producers and distributors include Max International, Inc. and LiveMax, LLC.

Those with a narrow margin are more difficult to dose and administer, and may require therapeutic drug monitoring (examples are warfarin, some antiepileptics, aminoglycoside antibiotics). Most anti-cancer drugs have a narrow therapeutic margin: toxic side-effects are almost always encountered at doses used to kill tumors. The effect of drugs can be described with Loewe additivity which is one of several common reference models. Other models include the Hill equation, Cheng–Prusoff equation and Schild regression.

=== Other awards === Fenn received his Nobel Prize fairly late in his career. Prior to being honored by the Nobel Foundation, Fenn had received numerous other awards. Early in his career, Fenn's research was focused on molecular beams, leading him to be named an honorary president of the Sixth International Symposium on Molecular Beams in 1977, and the first fellow of the International Molecular Beam Symposium in 1985. In 1982, the Alexander von Humboldt Foundation presented him with their U.S. Senior Scientist Award. Fenn's work in mass spectrometry earned him another spate of awards later in his career. In 1992, the American Society for Mass Spectrometry presented him with their Award for Distinguished Contributions in Mass Spectrometry. The International Society of Mass Spectrometry honored him with the Thomson Medal in 2000, and in the same year the American Chemical Society presented him with the Award for Advancements in Chemical Instrumentation. He was awarded the Association of Biomolecular Resource Facilities Award for outstanding contributions to Biomolecular Technologies in 2002. In 2003, Fenn was honored by his alma mater with the Wilbur Cross Medal, the Yale Graduate School Alumni Association's highest honor. Fenn maintained numerous professional affiliations, including membership in the American Chemical Society, the American Society for Mass Spectrometry, Sigma Chi, the American Association of University Professors and the Alexander von Humboldt Association of America.

Sources: en.wikipedia.org

Reference notes

== The Establishment of Institute of Biological Chemistry, Academia Sinica == Despite his significant scientific achievements, Dr. Li was also dedicated to the initiation and development of protein research in Taiwan. In spring 1958, Dr. Li was invited by Dr. Shih Hu to lecture a three-week course regarding the newly developed technology in protein chemistry and his latest pituitary gland research at National Taiwan University with the support from China Foundation for the Promotion of Education and Culture. At that time, the academic community only knew that protein research was developing rapidly abroad and a scholar had already made extraordinary achievements, and so when Dr. Li introduced the first-hand knowledge, it really attracted and inspired domestic scientists. Dr. Li believed that the protein chemistry was the foundation of future biochemical and biological sciences research, so he decided to assist the establishment of domestic protein research institute. In order to cultivate talents in Taiwan, Dr. Li personally provided scholarships and selected and persuaded scholars who have settled in Taiwan to continue the research in his or other research institutes. With the support from Academia Sinica, National Science Council, Ministry of Education, and National Taiwan University, Institute of Biological Chemistry and Institute of Biochemical Sciences, College of Life Science, National Taiwan University were established in 1972.

=== December 2004 === Reports of mock executions by the US Marines in Iraq have surfaced in December 2004, as the ACLU published internal documents of the Naval Criminal Investigative Service (NCIS) obtained through the Freedom of Information Act. The documents were written seven weeks after the publication of the photographs which triggered the Abu Ghraib prisoner abuse scandal. Several torture cases were also reported, notably torture by electricity, beatings, and sprayings of prisoners with fire extinguishers. On 21 December, the ACLU released further documents documenting tortures. Notably, in a case of shooting of suspects without warning, Army commanders are reported to have interfered with the investigation. Procedures of autopsy of detainees who died in unclear circumstances have been canceled by battalion and group commands. Other cases include

The source of blood to be transfused can either be the potential recipient (autologous transfusion) or someone else (allogeneic or homologous transfusion). The latter is much more common than the former. Using another's blood must first start with the donation of blood. Blood is most commonly donated as whole blood obtained intravenously and mixed with an anticoagulant. In first-world countries, donations are usually anonymous to the recipient, but products in a blood bank are always individually traceable through the whole cycle of donation, testing, separation into components, storage, and administration to the recipient. This enables management and investigation of any suspected transfusion-related disease transmission or transfusion reaction. Developing countries rely heavily on replacement and remunerated donors rather than voluntary nonremunerated donors due to concerns regarding donation- and transfusion-transmitted infection as well as local and cultural beliefs. It is unclear whether applying an alcohol swab alone or an alcohol swab followed by an antiseptic can reduce contamination of the donor's blood. Studies show that the main motivators to blood donation tend to be prosocial (e.g., altruism, selflessness, charity), while the main deterrents include fear, distrust, or perceived racial discrimination in historic contexts.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

Network